WS Investor
30 Jul 2026, 15:38
Bristol Myers Squibb Rises After Strong Q2 Results and Higher 2026 Outlook
Bristol Myers Squibb (NYSE: BMY) shares rose 1% on Thursday after the drugmaker reported strong second-quarter results and raised its full-year 2026 guidance, as investors welcomed continued momentum across the company's growth portfolio and improving earnings outlook.
Second-quarter revenue increased 6% year over year to $13.0 billion, while non-GAAP earnings per share rose 40% to $2.04. GAAP EPS climbed to $1.62 from $0.64 a year earlier, reflecting another quarter of solid earnings execution. The company also raised its full-year revenue outlook to approximately $49.0-$50.0 billion and increased its non-GAAP EPS guidance to a range of $6.75-$7.00.
Growth Portfolio Continues to Drive Performance
Bristol Myers' Growth Portfolio generated $7.6 billion in revenue, up 15% from a year ago, accounting for the majority of the company's sales. Growth was fueled by strong demand for newer therapies including Reblozyl, Camzyos, Breyanzi, Opdualag and Opdivo Qvantig.
Camzyos revenue surged 60%, Breyanzi climbed 41%, while Reblozyl increased 29%, highlighting the company's successful transition toward newer, high-growth medicines.
Meanwhile, the Legacy Portfolio declined 4%, as continued growth in Eliquis was more than offset by expected generic competition for products such as Revlimid and Pomalyst.
Pipeline Progress Supports Long-Term Outlook
Management highlighted continued progress across its pipeline and emphasized that the growing contribution from newer products positions the company for sustainable long-term growth. The higher full-year guidance reflects confidence in continued commercial execution and the momentum of recently launched therapies.
What to Watch
The positive share reaction suggests investors are focusing on Bristol Myers' accelerating growth portfolio and improved earnings outlook despite ongoing patent headwinds for legacy products. Going forward, markets will closely monitor continued adoption of the company's newer therapies, upcoming clinical trial results and its ability to offset declining legacy drug sales with sustained growth from recently launched medicines.
Bristol Myers Squibb (NYSE: BMY) shares rose 1% on Thursday after the drugmaker reported strong second-quarter results and raised its full-year 2026 guidance, as investors welcomed continued momentum across the company's growth portfolio and improving earnings outlook.
Second-quarter revenue increased 6% year over year to $13.0 billion, while non-GAAP earnings per share rose 40% to $2.04. GAAP EPS climbed to $1.62 from $0.64 a year earlier, reflecting another quarter of solid earnings execution. The company also raised its full-year revenue outlook to approximately $49.0-$50.0 billion and increased its non-GAAP EPS guidance to a range of $6.75-$7.00.
Growth Portfolio Continues to Drive Performance
Bristol Myers' Growth Portfolio generated $7.6 billion in revenue, up 15% from a year ago, accounting for the majority of the company's sales. Growth was fueled by strong demand for newer therapies including Reblozyl, Camzyos, Breyanzi, Opdualag and Opdivo Qvantig.
Camzyos revenue surged 60%, Breyanzi climbed 41%, while Reblozyl increased 29%, highlighting the company's successful transition toward newer, high-growth medicines.
Meanwhile, the Legacy Portfolio declined 4%, as continued growth in Eliquis was more than offset by expected generic competition for products such as Revlimid and Pomalyst.
Pipeline Progress Supports Long-Term Outlook
Management highlighted continued progress across its pipeline and emphasized that the growing contribution from newer products positions the company for sustainable long-term growth. The higher full-year guidance reflects confidence in continued commercial execution and the momentum of recently launched therapies.
What to Watch
The positive share reaction suggests investors are focusing on Bristol Myers' accelerating growth portfolio and improved earnings outlook despite ongoing patent headwinds for legacy products. Going forward, markets will closely monitor continued adoption of the company's newer therapies, upcoming clinical trial results and its ability to offset declining legacy drug sales with sustained growth from recently launched medicines.
